Logo image of SCPX

SCORPIUS HOLDINGS INC (SCPX) Stock Fundamental Analysis

USA - NYSEARCA:SCPX - US42237K5083 - Common Stock

0.068 USD
-0.06 (-48.48%)
Last: 4/21/2025, 8:04:00 PM
Fundamental Rating

2

Overall SCPX gets a fundamental rating of 2 out of 10. We evaluated SCPX against 536 industry peers in the Biotechnology industry. Both the profitability and financial health of SCPX have multiple concerns. SCPX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCPX has reported negative net income.
In the past year SCPX has reported a negative cash flow from operations.
SCPX had negative earnings in each of the past 5 years.
In the past 5 years SCPX always reported negative operating cash flow.
SCPX Yearly Net Income VS EBIT VS OCF VS FCFSCPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

SCPX has a Return On Assets of -72.96%. This is in the lower half of the industry: SCPX underperforms 66.49% of its industry peers.
SCPX's Return On Equity of -128.83% is on the low side compared to the rest of the industry. SCPX is outperformed by 60.32% of its industry peers.
Industry RankSector Rank
ROA -72.96%
ROE -128.83%
ROIC N/A
ROA(3y)-53.06%
ROA(5y)-51.43%
ROE(3y)-77.93%
ROE(5y)-80.68%
ROIC(3y)N/A
ROIC(5y)N/A
SCPX Yearly ROA, ROE, ROICSCPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

With an excellent Gross Margin value of 68.54%, SCPX belongs to the best of the industry, outperforming 80.60% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SCPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPX Yearly Profit, Operating, Gross MarginsSCPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

SCPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCPX has been increased compared to 1 year ago.
The number of shares outstanding for SCPX has been increased compared to 5 years ago.
The debt/assets ratio for SCPX is higher compared to a year ago.
SCPX Yearly Shares OutstandingSCPX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
SCPX Yearly Total Debt VS Total AssetsSCPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.40, we must say that SCPX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.40, SCPX is doing worse than 72.66% of the companies in the same industry.
A Debt/Equity ratio of 0.31 indicates that SCPX is not too dependend on debt financing.
The Debt to Equity ratio of SCPX (0.31) is worse than 71.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACC4.43%
SCPX Yearly LT Debt VS Equity VS FCFSCPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.38 indicates that SCPX may have some problems paying its short term obligations.
The Current ratio of SCPX (0.38) is worse than 94.36% of its industry peers.
A Quick Ratio of 0.26 indicates that SCPX may have some problems paying its short term obligations.
The Quick ratio of SCPX (0.26) is worse than 95.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.26
SCPX Yearly Current Assets VS Current LiabilitesSCPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.42% over the past year.
The Revenue has grown by 947.53% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 3.85% on average over the past years.
EPS 1Y (TTM)20.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68%
Revenue 1Y (TTM)947.53%
Revenue growth 3Y33.35%
Revenue growth 5Y3.85%
Sales Q2Q%356.36%

3.2 Future

SCPX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.10% yearly.
SCPX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.70% yearly.
EPS Next Y97.7%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year63.27%
Revenue Next 2Y80.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SCPX Yearly Revenue VS EstimatesSCPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
SCPX Yearly EPS VS EstimatesSCPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SCPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPX Price Earnings VS Forward Price EarningsSCPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPX Per share dataSCPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as SCPX's earnings are expected to grow with 41.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SCPX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCORPIUS HOLDINGS INC

NYSEARCA:SCPX (4/21/2025, 8:04:00 PM)

0.068

-0.06 (-48.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)05-26 2025-05-26
Inst Owners0.19%
Inst Owner ChangeN/A
Ins Owners0.71%
Ins Owner Change0%
Market Cap331.16K
Analysts82.86
Price Target5.1 (7400%)
Short Float %0.13%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-4.74
FCFYN/A
OCF(TTM)-4.61
OCFYN/A
SpS2
BVpS5.87
TBVpS5.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.96%
ROE -128.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.54%
FCFM N/A
ROA(3y)-53.06%
ROA(5y)-51.43%
ROE(3y)-77.93%
ROE(5y)-80.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.24%
Cap/Sales 6.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.26
Altman-Z -9.4
F-Score3
WACC4.43%
ROIC/WACCN/A
Cap/Depr(3y)326.96%
Cap/Depr(5y)240.26%
Cap/Sales(3y)144.6%
Cap/Sales(5y)90.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68%
EPS Next Y97.7%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)947.53%
Revenue growth 3Y33.35%
Revenue growth 5Y3.85%
Sales Q2Q%356.36%
Revenue Next Year63.27%
Revenue Next 2Y80.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.43%
OCF growth 3YN/A
OCF growth 5YN/A